LOGO
LOGO

Email This Article

Immutep Initiates Phase III TACTI-004 Trial Of Eftilagimod Alfa In First-Line NSCLC
To Email: *
Bcc: Seperate multiple addresses with commas(,)
Your Email: *
Format :

* Denotes Required Fields